Wiley and OpenEvidence Partner to Deliver Trusted Research to Physicians at the Point of Care
MWN-AI** Summary
Wiley, a leading publisher in scientific content and research intelligence, has partnered with OpenEvidence, a prominent medical AI platform, to enhance the access and reliability of medical literature for clinicians at the point of care. This strategic collaboration aims to integrate Wiley’s extensive collections of peer-reviewed journals and medical resources into OpenEvidence, allowing physicians to access high-quality, evidence-based material effortlessly as they make clinical decisions.
The partnership addresses a pressing challenge in the medical field: despite the rapid growth of biomedical research, significant delays persist in translating findings into practice, often taking around 17 years. With medical knowledge doubling every 73 days, the need for efficient retrieval of trustworthy information has never been more critical. OpenEvidence will incorporate not only a vast array of Wiley's academic materials, including the esteemed Cochrane Database of Systematic Reviews, but also over 400 additional journals and books covering various medical specialties such as oncology, cardiology, and neurology.
This collaboration emphasizes the importance of having peer-reviewed content as the backbone of AI-driven medical decision-making tools; it ensures that the information clinicians receive is not only accurate but also grounded in established research. Daniel Nadler, founder of OpenEvidence, highlighted the partnership's potential to narrow the long-standing gap between published research and clinical practice, enhancing care delivery and improving patient outcomes.
In summary, the union of Wiley's authoritative scholarly content with OpenEvidence's AI capabilities promises to significantly empower healthcare professionals by streamlining their access to reliable information, ultimately fostering better decision-making and patient care in real-time clinical scenarios.
MWN-AI** Analysis
The strategic partnership between Wiley and OpenEvidence signifies a promising advancement in the integration of authoritative medical content with AI technology, fundamentally enhancing clinical decision-making at the point of care. For investors, this collaboration presents several key considerations.
1. **Market Positioning**: Wiley’s position as a leading provider of scientific and medical content, combined with OpenEvidence's extensive user base among U.S. physicians, creates a formidable alliance. This partnership is poised to expand both companies' market influence within the healthcare technology sector, appealing to a growing demand for reliable information amidst exponential medical knowledge growth.
2. **Increased Analytics and AI Adoption**: With Over 400 medical journals, including critical resources like the Cochrane Database, Wiley's content will enhance OpenEvidence's capabilities. This integration allows for trusted, evidence-based answers to clinical questions, which can streamline workflows, reduce costly search times, and ultimately bolster patient care. Companies harnessing AI in clinical settings are likely to attract investment, positioning them favorably in a market that values efficiency and accuracy.
3. **Future Growth Opportunities**: The partnership hints at future collaborative projects that could deepen industry connections and foster global expansion. Investors should consider the potential for revenue increases derived from new offerings due to richer content aggregation, which could broaden the appeal of both Wiley and OpenEvidence to other healthcare practitioners and organizations.
4. **Mitigating Clinical Gaps**: By bridging the longstanding gap between published research and clinical practice, this partnership addresses a critical issue in healthcare. A strategic focus here could enhance the companies' reputations within the industry, attracting more users and reinforcing their competitive edge.
In summary, the Wiley and OpenEvidence collaboration not only strengthens their current value propositions but also opens avenues for expansive growth in a rapidly evolving healthcare landscape. Investors would do well to monitor this partnership's development and its impact on both companies' future performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
A new content agreement deepens the medical literature physicians can retrieve, synthesize, and verify through AI-assisted clinical questions
Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of clinical practice, scientific discovery and learning, and OpenEvidence, the most widely used medical AI platform in the world, today announced a strategic partnership to bring Wiley's trusted scientific and medical content into OpenEvidence. Through the partnership, physicians using OpenEvidence at the point of care can rely on content from hundreds of Wiley’s peer-reviewed journals and resources across key medical specialties to support their clinical decisions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303408088/en/
Medical knowledge doubles every 73 days. Historically, published research has taken an average of 17 years to reach clinical practice. Helping doctors make point-of-care decisions grounded in the best and latest science requires more than capable AI; it needs the right underlying content. OpenEvidence was built on a principle its founders call “gold in, gold out”: specialized models trained on peer-reviewed literature, not the open internet, with every answer grounded in sources a physician can drill into and verify. By joining OpenEvidence’s existing network of content partners, Wiley extends that foundation.
“The hard problem in medicine right now isn’t just generating new knowledge. We are living through a golden age of biomedical research. The hard problem is also that it takes 17 years for a fraction of that research to reach the bedside,” said Daniel Nadler, founder of OpenEvidence. “Wiley is an ideal partner in solving this problem for physicians. The depth and breadth of Wiley’s content reinforce the advantages of OpenEvidence for physicians, and that compounds over time.”
Wiley will license a comprehensive portfolio of scientific and medical content to OpenEvidence, including the Cochrane Database of Systematic Reviews —the home of gold standard evidence syntheses, widely used to inform clinical guidelines worldwide—and Cochrane Clinical Answers —a curated collection of actionable clinical insights drawn from Cochrane reviews.
“Cochrane systematic reviews are relied upon by evidence users worldwide, from patients and healthcare professionals to guideline-setters and policymakers,” said Karla Soares-Weiser, CEO of Cochrane. “AI is rapidly changing the ways that people use and access evidence, and we hope that this partnership helps to ensure that outputs from AI-powered tools are based on the best possible evidence.”
Additionally, the portfolio will comprise over 400 Wiley journals and books, including authoritative medical references such as Holland-Frei Cancer Medicine , Rook's Dermatology Handbook, and Yamada's Textbook of Gastroenterology . The content, which spans medical specialties including cardiology, endocrinology, geriatrics, hematology, internal medicine, neurology, obstetrics, oncology, psychiatry, and rheumatology, will be referenced inside OpenEvidence’s evidence layer, cited with the same transparency that has earned the platform the trust of more than 40% of U.S. physicians.
For clinicians, the practical effect is broader and deeper access to trustworthy evidence at the point of care. The question a physician encounters once in a career is often the one where the evidence is most essential and where a dead-end search carries the highest cost. Wiley's corpus deepens the literature available in OpenEvidence for precisely those queries, expanding the range of clinical questions that return a source-cited, evidence-based answer without leaving the point-of-care workflow.
“At the end of the day, we believe doctors will be able to make better decisions because we’re bringing Wiley’s vast portfolio of peer-reviewed scientific and medical content into OpenEvidence, where those decisions are getting made,” said Matt Kissner, president and CEO of Wiley. “We’re excited about this partnership, which reflects our broader commitment to integrating trusted scientific knowledge into the technologies driving innovation across healthcare and life sciences.”
The partnership positions Wiley and OpenEvidence to explore future collaboration opportunities together, including deepening society relationships, connections across networks, global expansion, and other healthcare and life sciences use cases.
“The gap between published research and clinical practice has persisted for decades. Every content partnership that puts peer-reviewed evidence directly into the physician’s workflow makes that gap narrower. This one makes it meaningfully so,” added Daniel Nadler.
About Wiley
Wiley (NYSE: WLY) is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact: Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com . Follow us on Facebook , X , LinkedIn and Instagram .
About OpenEvidence
OpenEvidence is the most widely used medical AI platform among U.S. physicians, and is trusted by hundreds of thousands of verified clinicians to make high-stakes clinical decisions at the point of care with answers that are sourced, cited, and grounded in peer-reviewed medical literature. OpenEvidence was founded with the mission to organize and expand the world's collective medical knowledge. Learn more at openevidence.com .
Category: All Corporate News
Category: All Journals and Research
View source version on businesswire.com: https://www.businesswire.com/news/home/20260303408088/en/
OpenEvidence
media@openevidence.com
Wiley
newsroom@wiley.com
FAQ**
How does the partnership between Wiley and OpenEvidence enhance the ability of physicians to retrieve and synthesize medical literature, particularly in light of the historical delays in research translation, as noted by John Wiley & Sons Inc. WLYB?
What specific benefits do the Cochrane Database of Systematic Reviews and Cochrane Clinical Answers bring to OpenEvidence users, and how does this collaboration position John Wiley & Sons Inc. WLYB in the evolving landscape of medical AI?
In what ways might the integration of over 400 Wiley journals and books into OpenEvidence improve clinical decision-making for physicians, considering the critical need for timely evidence in practice, according to John Wiley & Sons Inc. WLYB?
What future collaborations or innovative strategies might emerge from the partnership between Wiley and OpenEvidence, especially regarding global expansion in healthcare access, as suggested by John Wiley & Sons Inc. WLYB?
**MWN-AI FAQ is based on asking OpenAI questions about John Wiley & Sons Inc. (NYSE: WLYB).
NASDAQ: WLYB
WLYB Trading
12.91% G/L:
$36.30 Last:
211 Volume:
$36.30 Open:
